<DOC>
	<DOCNO>NCT01669447</DOCNO>
	<brief_summary>Significant difference parameter setting early optical coherence tomography ( OCT spectal domain ) patient subfoveal neovascular membrane realacionada age treatment single intravitreal injection Lucentis .</brief_summary>
	<brief_title>Evaluation Changes Parameters Optical Coherence Tomography After Intravitreal Injection Lucentis</brief_title>
	<detailed_description>Assessment early change parameter optical coherence tomography ( OCT spectral domain ) patient subfoveal neovascularization secondary age-related degeneration treatment single intravitreal injection Lucentis . Age-related macular degeneration ( AMD ) lead cause blindness 50 year develop Western country . Its prevalence increase age affect 8.5 27.9 % population 75 year . Its incidence increase 30-40 % recent decade , spite eye disease cataracts glaucoma , reach population group , show apparently reduce record . Although approximately 80 % patient AMD neovascular form , neovascular form responsible almost 90 % severe visual loss result AMD . It create great socioeconomic impact , become public health problem . Quantitative analysis OCT show increase clinical importance development anti-VEGF therapy evaluate outcome treatment neovascular AMD . Relatively study AMD propose examine correlation morphological parameter OCT BCVA systematic way . It important assess impact different OCT parameter visual acuity early 7 day intravitreal injection ranibizumab patient AMD define parameter correlate good AV prognosis . It also unknown patient ' perception effectiveness treatment early stage . For evaluation , apply visual function questionnaire ( VFQ - 25 ) 1 7 day treatment .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Keratoconus</mesh_term>
	<mesh_term>Color Vision Defects</mesh_term>
	<mesh_term>Choroid Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female &gt; 50 year sign consent form BCAV 20/40 20/320 ( Snellen equivalent determine use ETDRS ) Have choroidal neovascularization associate AMD , lesion involve fovea assess use fluorescein angiography fundus Background subfoveal choroidal neovascularization recent development constructive AMD disease , observe presence blood , decrease AV recent recent increase diameter range 10 % . Concomitant disease eye condition eye disorder may confound interpretation study result affect visual acuity require medical surgical intervention 30 day study period , include retinal vascular occlusion , retinal detachment macular hole . Eye Treatments laser photocoagulation panretiniana eye study 6 month less focal / grid photocoagulation eye study less 3 month entry study treatment antiangiogenic intravitreal steroid eye study 4 month randomization Any intraocular surgery eye study 3 month History randomization vitrectomy eye condition study ocular study eye require concomitant therapy corticosteroid oral topical . Condition Treatment systemic history disease , metabolic dysfunction , physical examination finding , laboratory suspect cause disease condition contraindicate use study drug , change interpretation study place patient risk complication treatment . And intractable severe hypertension ( diastolic blood pressure &gt; 160 mmHg diastolic &gt; 100 mmHg ) Use drug know toxic lens , retina optic nerve include Deferoxamine , chloroquine , tamoxifen , fenotiazines , ethambutol . Known hypersensitivity ranibizumab component prior Administrative Participation patient study clinical investigative drug ( exclude vitamin mineral ) 6 month ( period correspond five halflives drug investigate great ) randomization Failure comply study procedure followup</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>dmri , mnvc , lucentis</keyword>
</DOC>